Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Other financing activities (2020 - 2023)

Inmune Bio's Other financing activities history spans 4 years, with the latest figure at $1.9 million for Q3 2023.

  • For Q3 2023, Other financing activities fell 2.58% year-over-year to $1.9 million; the TTM value through Sep 2023 reached $7.4 million, up 7.92%, while the annual FY2021 figure was $4.8 million, 54.11% up from the prior year.
  • Other financing activities for Q3 2023 was $1.9 million at Inmune Bio, up from $1.9 million in the prior quarter.
  • Across five years, Other financing activities topped out at $1.9 million in Q3 2022 and bottomed at $681000.0 in Q2 2020.
  • The 4-year median for Other financing activities is $1.5 million (2021), against an average of $1.3 million.
  • The largest annual shift saw Other financing activities soared 145.25% in 2022 before it dropped 2.58% in 2023.
  • A 4-year view of Other financing activities shows it stood at $703000.0 in 2020, then skyrocketed by 116.5% to $1.5 million in 2021, then increased by 27.4% to $1.9 million in 2022, then decreased by 2.58% to $1.9 million in 2023.
  • Per Business Quant, the three most recent readings for INMB's Other financing activities are $1.9 million (Q3 2023), $1.9 million (Q2 2023), and $1.7 million (Q1 2023).